-
10.04.2023 | Day Zero Diagnostics welcomes microbiology and genomic researcher Dr. Patricia Simner to advisory board
Day Zero Diagnostics Inc. (DZD), an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the addition of Patricia (Trish) Simner, Ph.D., M.Sc., to its clinical advisory board
-
09.20.2023 | Day Zero Diagnostics announces completion of $16M financing round
This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.
-
09.19.2023 | Peptilogics reports positive 180-day top line interim data from phase 1b trial of Plg0206 in patients with Periprosthetic Joint Infection (Pji)
In both patient cohorts followed for six months after PLG0206 treatment, there were no treatment-related serious adverse events and no recurrence was observed in 13 of 14 (93%) treated patients at Day-180 in contrast to reported 180-day success rate of 45%.
-
07.31.2023 | Pattern Bioscience selected as winner of ADLM Disruptive Technology Award
Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, today announced that it was named the winner of the Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine.
-
07.27.2023 | Bugworks: GARDP and Bugworks join forces to accelerate development of a novel antibiotic to treat serious bacterial infections
The Global Antibiotic Research & Development Partnership (GARDP) is joining forces with Bugworks Research Inc. to accelerate the development of a new broad-spectrum antibiotic compound aimed at treating serious infections caused by multidrug-resistant bacteria.
-
07.12.2023 | SpeeDx announce expansion of their research offering.
SpeeDx Pty. Ltd., have released a new Research Use Only (RUO) product providing an exciting expansion of their research offering. CT/GC/TV/MGPlex* simultaneously detects Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) in a single-well multiplex qPCR/NAAT assay.
-
06.20.2023 | Speedx: Adjunct Professor Alison Todd, FTSE PhD awarded Member (AM) in the general division of the Order of Australia
Adjunct Professor Alison Todd, AM FTSE PhD, a distinguished figure in the field of medical research and tertiary education, has been recognized for her exceptional contributions and honoured as a Member (AM) in the General Division of the Order of Australia.
-
06.12.2023 | Avails Medical’s eQUANT™ system submitted to FDA for 510(k) clearance
The eQUANT system provides a standardized inoculum (0.5 McFarland equivalent) directly from a positive blood culture, which is designed to be used with traditional automated AST systems and Disk Diffusion, accelerating routine AST turnaround times by up to one day.
-
05.08.2023 | Vedanta Biosciences receives fast track designation for VE303 and presents phase 2 data at digestive disease week
VE303 receives Fast Track designation for prevention of recurrent C. difficile infection ahead of global pivotal Phase 3 study
-
04.27.2023 | Pattern Bioscience secures $28.7 million in Series C financing
New funding will be used to accelerate development of first-of-its-kind infectious disease diagnostic platform that will deliver rapid antibiotic treatment guidance
-
04.25.2023 | Vedanta Biosciences announces $106.5 million financing to advance pipeline of defined bacterial consortia therapies
Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023
-
03.01.2023 | SpeeDx raises $26 million to accelerate new technology development and commercial expansion
SpeeDx Pty. Ltd., a developer of transformative molecular diagnostic solutions, has today announced a raise of $26 million from a range of investors including Northpond Ventures, Platinum Asset Management and Tenmile.
-
01.24.2023 | Lumen Bioscience receives broad funding support for advancement of antibiotic alternative for preventing traveler’s diarrhea
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases.
Toggle navigation